Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Common Equity (2016 - 2022)

Historic Common Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$12.4 million.

  • Avadel Pharmaceuticals' Common Equity fell 11257.11% to -$12.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$12.4 million, marking a year-over-year decrease of 11257.11%. This contributed to the annual value of $78.2 million for FY2021, which is 5178.04% down from last year.
  • Per Avadel Pharmaceuticals' latest filing, its Common Equity stood at -$12.4 million for Q3 2022, which was down 11257.11% from -$3.3 million recorded in Q2 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Common Equity registered a high of $182.1 million during Q2 2020, and its lowest value of -$29.2 million during Q4 2019.
  • Its 5-year average for Common Equity is $56.2 million, with a median of $55.2 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 115032.37% in 2019, then surged by 112449.79% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Common Equity (Quarter) stood at $2.8 million in 2018, then crashed by 1150.32% to -$29.2 million in 2019, then soared by 655.72% to $162.3 million in 2020, then tumbled by 51.78% to $78.2 million in 2021, then plummeted by 115.9% to -$12.4 million in 2022.
  • Its Common Equity stands at -$12.4 million for Q3 2022, versus -$3.3 million for Q2 2022 and $55.2 million for Q1 2022.